Javier Morales

This inventor holds 5 USPTO granted patents and 1 published patent application and 2 EPO patents. Top assignees: Eureka Therapeutics, Inc., Memorial Sloan Kettering Cancer Center. Active years: 2022-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Javier Morales. Retrieved from https://idiyas.com/inventor/javier-morales-ymaxkak4

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 5 (Patent Applications = 1)

% Patents Active = 100.0

EPO Patents = 2 (Patent Applications = 1)

Average Co-Inventor Count = 6.4

ph-index = 1

Forward Citations = 1(Granted Patents)

Location History:

San Jose, CA (US) (2022 - 2023)
Emeryville, CA (US) (2023)

Company Filing History:

5 out of 52

Eureka Therapeutics, Inc.

patents

1 out of 621

Memorial Sloan Kettering Cancer Center

patents

where one patent can have more than one assignee

Years Active: 2022-2025

Loading Chart...

5 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12479924 - CONSTRUCTS SPECIFICALLY RECOGNIZING GLYPICAN 3 AND USES THEREOF (2025-11-25),

2. 12168696 - Antibodies to mucin-16 (MUC16), encoding polynucleotides and methods of treating MUC16-positive cancer (2024-12-17),

3. 11827672 - Constructs trageting CD22 and uses thereof (2023-11-28),

4. 11613573 - Chimeric antibody/T-cell receptor constructs and uses thereof (2023-03-28),

5. 11447564 - Constructs specifically recognizing glypican 3 and uses thereof (2022-09-20),

Title: The Innovative Contributions of Javier Morales

Introduction

Javier Morales is a prominent inventor based in San Jose, CA, known for his significant contributions to the field of cancer research. With a total of four patents to his name, he has made strides in developing therapeutic methods targeting specific cancer markers.

Latest Patents

Among his latest patents is a groundbreaking work on antibodies to mucin-16 (MUC16), which includes encoding polynucleotides and methods for treating MUC16-positive cancer. This patent provides compositions, methods, and uses involving anti-Mucin-16 agents that immunospecifically bind to an epitope of Mucin-16. Additionally, he has developed constructs targeting CD22, which describes antibodies and constructs that bind to the extracellular domain of CD22. These innovations are particularly relevant for the therapeutic treatment of diseases characterized by CD22 expression, such as B-cell lymphomas and leukemias.

Career Highlights

Javier has worked with notable organizations, including Eureka Therapeutics, Inc. and Memorial Sloan Kettering Cancer Center. His work in these institutions has allowed him to advance his research and contribute to significant developments in cancer treatment.

Collaborations

Some of his notable coworkers include Hong Liu and Yiyang Xu, who have collaborated with him on various projects aimed at enhancing cancer therapies.

Conclusion

Javier Morales continues to be a key figure in the field of cancer research, with his innovative patents paving the way for new treatment methods. His work exemplifies the impact of dedicated inventors in advancing medical science.

Profile summary based on public USPTO records.